An interventional study of CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES in Coronary Artery Disease, Mitral Valve Regurgitation and Mitral Valve Incompetence, sponsored by Edwards Lifesciences. Completed at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by Edwards Lifesciences · Not applicable, Interventional, and Treatment
The purpose of the study is to demonstrate the long term safety and effectiveness of the Carpentier-Edwards® PERIMOUNT Magna Mitral Valves in patients undergoing mitral valve replacement with or without concomitant procedures requiring cardiopulmonary bypass.
This is a prospective, single-arm, multi-center study to be conducted in the US and outside the US (OUS). Approximately 250 subjects are planned to be enrolled to obtain long term data from 101 subjects at 8 years post implant of the Magna mitral valve. Of these 250, approximately 38 (15%) are anticipated to be simultaneous aortic and mitral replacements. Subject enrollment will not start in the US before obtaining FDA approval of this post market study.
Assessments will be obtained for the preoperative and operative visits, and postoperatively at discharge, six months, 1-year and annually thereafter for a minimum of 8 years. Subject's demographics (date of birth, sex), physical assessment (heart rate, height, weight, systolic and diastolic blood pressures), New York Heart Association (NYHA) functional class, cardiac rhythm, cardiovascular medical history/risk factors, non-cardiovascular conditions, previous cardiovascular procedures/interventions, antithromboembolic and lipid lowering medications and coagulation profile. Blood data will be collected from each subject preoperatively, at 6 months and annually post implant through 8 year follow-ups. Echocardiographic evaluation required for each subject preoperatively, at discharge, 6 months (between 3-6 months), 1, 2, 4, 6, and 8 year follow-ups. A QOL survey (EQ-5D) will be completed by the subject pre-operatively and at the 6-month follow-up visit.
5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.
This study's enrollment of 329 is above the median of 124 across 3,436 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Edwards Lifesciences is the lead sponsor of 124 studies on the registry; 19 are open to participants now.
Of its 34 completed or terminated interventional studies of FDA-regulated products, 32 (94%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES
Mitral valve replacement
Also known as: Magna Mitral 7000/7000TFX, Magna Mitral Ease 7200TFX, 7300/7300TFX
Subject's Rate of Objective Performance Criteria Per ISO 5840-2005 - Total Number of Late Adverse Events (by Category) Divided by Late Patient Years (Expressed as a Percentage) for the Magna Mitral Valve Implanted Cohort
A linearized rate percentage is calculated by the following equation: \[(Total number of late adverse events in each category/total number of late patient years) x 100\]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact.
Time frame: Events occurring ≥ 31 days and up through 8 years post-implant
Primary Effectiveness Endpoints
The primary effectiveness endpoint will be the percentage of subjects in NYHA functional classification I or II at 8 years post-implant.
Time frame: 8 years post-implant
Percent of Early Adverse Events
Total number of early adverse events, in each category, occurring within 30 days of procedure divided by the number of enrolled subjects times 100.
Time frame: Events occurring within 30 days of procedure
Subject's Average Score on the EQ-5D - Quality of Life Questionnaire Over Time
The EQ-5D is a standardized questionnaire that asks subjects to rate themselves (no problems, some problems, extreme problems) on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scale ranges from a minimum of 0 and a maximum of 100. A lower number indicates the participants experiences more problems and a higher number indicates the participants experiences fewer problems.
Time frame: 6 months post-implant
Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage) for the Magna Mitral Valve Implanted Cohort
A linearized rate percentage is calculated by the following equation: \[(Total number of late adverse events in each category/total number of late patient years) x 100\]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact.
Time frame: Events occurring ≥ 31 days and up through 8 years post-implant
Subject's Average Mean Gradient Measurement
Mean gradient is the average flow of blood through the mitral valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.
Time frame: Baseline and 8 years post-implant
Subject's Average Peak Gradient Measurement
Peak gradient is the maximum value measured of flow of blood through the mitral valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher valve is considered worse, and a lower value is considered better, but the value is dependent on the size and type of valve.
Time frame: Baseline and 8 years post-implant
Subject's Average Effective Orifice Area (EOA) Measurement
Effective orifice area represents the cross-sectional area of the blood flow downstream of the mitral valve. Effective orifice area is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size and type of valve.
Time frame: Baseline and 8 years post-implant
Subject's Average Effective Orifice Area Index (EOAI) Measurement
Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the mitral valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size of the patient and the size and type of valve.
Time frame: Baseline and 8 years post-implant
Subject's Average Cardiac Output Measurement
Cardiac output is the amount of blood the heart pumps through the circulatory system in a minute. Cardiac output is evaluated by echocardiography over time. Normal cardiac output in healthy volunteers over 60 years of age was reported between 3.1 and 6.4 liters per minute. In general, a higher value is considered better, and a lower value is considered worse.
Time frame: Baseline and 8 years post-implant
Subject's Average Cardiac Index Measurement
Cardiac index (CI) evaluated by echocardiography. Cardiac index is an assessment of the cardiac output value based on the patient's size. To obtain the cardiac index, divide the cardiac output by the person's body surface area (BSA). Cardiac Index is a useful marker of how well the heart is functioning as a pump by directly correlating the volume of blood pumped by the heart with an individual's body surface area. Normal cardiac output index in healthy volunteers over 60 years of age was reported between 1.1 and 3.2 L/min/m\^2. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size of the patient.
Time frame: Baseline and 8 years post-implant
Subject's Average Left Ventricular Mass Regression
Patients can experience an enlargement of the left ventricle (chamber) of their heart because it works harder with a defective heart valve. Left ventricular mass regression evaluates if the patient experiences a decrease in the size of the left ventricle (chamber) after the repair or replacement of their heart valve.
Time frame: Baseline and 8 years post-implant
Subject's Average Red Blood Cell Count
The red blood cell (RBC) count is a test that measures the number of oxygen-carrying blood cells in your blood. The red blood cell count normal range for women is 4.2 to 5.4 10\^6 cells/microliters and for men is 4.7 to 6.1 10\^6 cells/microliters. A high red blood cell count may indicate that you have a condition that's preventing you from getting enough oxygen. A low RBC may be caused by an infection, or a medical condition related to anemia. In general, results either lower or higher than the normal range may indicate something is wrong.
Time frame: 6-month, 1-year, 2-year, 3-year, 4-year, 5-year, 6-year, 7-year, and 8-year follow-up visits
Subject's Average White Blood Cell Count
Laboratory analysis of White Blood Cell (WBC) count on blood drawn from subject; WBC fight infection. The normal reference range for WBC count is 4.5 to 10.0 10\^3 cells/microliters. In general, results either lower or higher than the normal range can indicate something is wrong.
Time frame: 6-month, 1-year, 2-year, 3-year, 4-year, 5-year, 6-year, 7-year, and 8-year follow-up visits
Subject's Average Hemoglobin Count
This is the laboratory analysis of Hemoglobin count on blood drawn from subjects. Hemoglobin is an oxygen-carrying protein in red blood cells. In males, a healthy hemoglobin level is between 13.2 and 16.6 g/dL. In females, a hemoglobin count of between 11.6 and 15 g/dL is considered normal and healthy. In general, results either lower or higher than the normal range can indicate something is wrong.
Time frame: 6-month, 1-year, 2-year, 3-year, 4-year, 5-year, 6-year, 7-year, and 8-year follow-up visits
Subject's Average Hematocrit Count
This is laboratory analysis of Hematocrit percentage on blood drawn from subjects. A hematocrit test measures the proportion of red blood cells in your blood. Red blood cells carry oxygen throughout your body. Having too few or too many red blood cells can be a sign of certain diseases. Normal hematocrit ranges for adult females are 36% to 44% and for adult males are 41% to 50%. In general, results either lower or higher than the normal range can indicate something is wrong.
Time frame: 6-month, 1-year, 2-year, 3-year, 4-year, 5-year, 6-year, 7-year, and 8-year follow-up visits
Subject's Average Reticulocytes Percentage Over Time
Laboratory Analysis of reticulocytes on blood drawn from subjects. Reticulocytes are newly produced immature red blood cells; a reticulocyte blood test measures the amount of these cells in the blood. The reference range for reticulocytes is 0.5 - 2.6 % of red blood cells. In general, results either lower or higher than the normal range can indicate something is wrong.
Time frame: 6-month, 1-year, 2-year, 3-year, 4-year, 5-year, 6-year, 7-year, and 8-year follow-up visits
Subject's Average Platelet Count Over Time
This is laboratory analysis of Platelet count on blood drawn from subjects. The purpose of platelets is to create hemostasis, which is the prevention of hemorrhaging (bleeding) and the process of keeping blood inside the vessel walls. A normal platelet range is 150 to 450 10\^3 cells/microliter. In general, results either lower or higher than the normal range can indicate something is wrong.
Time frame: 6-month, 1-year, 2-year, 3-year, 4-year, 5-year, 6-year, 7-year, and 8-year follow-up visits
Subject's Average Serum Lactate Dehydrogenase (LDH) Over Time
The serum lactate dehydrogenase (LDH) test looks for signs of damage to the body's tissues. Normal levels of LDH in the blood can vary depending on the lab but usually range between 140 units per liter (U/L) to 280 U/L for adults and tend to be higher for children and teens. In general, results either lower or higher than the normal range can indicate something is wrong.
Time frame: 6-month, 1-year, 2-year, 3-year, 4-year, 5-year, 6-year, 7-year, and 8-year follow-up visits
Subject's Average Plasma Free Hemoglobin Over Time
Laboratory analysis of Plasma Free Hemoglobin (Pf Hgb) of blood drawn from subject. This blood test measures the level of free hemoglobin in the plasma (liquid portion of the blood). The reference range for plasma free hemoglobin is 0.0 to 15.2 mg/dL. In general, values higher than this can indicate something is wrong.
Time frame: 6-month, 1-year, 2-year, 3-year, 4-year, 5-year, 6-year, 7-year, and 8-year follow-up visits
Subject's Average Haptoglobin Over Time
Haptoglobin is a protein produced by your liver. It binds with hemoglobin, which is a protein found in red blood cells. When red blood cells are destroyed, they release hemoglobin. The released hemoglobin is called "free hemoglobin." Haptoglobin attaches to the free hemoglobin to create a haptoglobin-hemoglobin complex. This complex travels to the liver, where it's removed from the body. A normal haptoglobin level falls between 45 and 200 milligrams of haptoglobin per deciliter of blood. In general, results either lower or higher than the normal range can indicate something is wrong.
Time frame: 6-month, 1-year, 2-year, 3-year, 4-year, 5-year, 6-year, 7-year, and 8-year follow-up visits
| Milestone | Device - CEP Mitral Valve |
|---|---|
| Started | 329 |
| Completed | 127 |
| Not completed | 202 |
| Withdrew: Death | 88 |
| Withdrew: Withdrawal by subject | 45 |
| Withdrew: Lost to follow-up | 30 |
| Withdrew: Reoperation/explant | 17 |
| Withdrew: Exit with other reason | 22 |
A linearized rate percentage is calculated by the following equation: \[(Total number of late adverse events in each category/total number of late patient years) x 100\]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact.
| Linearized rate percentage | Device - CEP Mitral Valve |
|---|---|
| Thromboembolism | 2.0 |
| All bleeding events | 5.8 |
| All paravalvular leak | 0.3 |
| Endocarditis | 0.3 |
The primary effectiveness endpoint will be the percentage of subjects in NYHA functional classification I or II at 8 years post-implant.
| Participants | Device - CEP Mitral Valve |
|---|---|
| Primary Effectiveness Endpoints | 93 |
Total number of early adverse events, in each category, occurring within 30 days of procedure divided by the number of enrolled subjects times 100.
| percentage | Device - CEP Mitral Valve |
|---|---|
| Thromboembolism | 2.1 |
| Valve Thrombosis | 0.0 |
| All Bleeding Events | 12.2 |
| Major bleeding | 9.4 |
| Endocarditis | 0.0 |
| Hemolysis | 0.0 |
| Structural Valve Deterioration | 0.0 |
| Non-Structural Valve Dysfunction | 1.5 |
| Reoperation | 0.9 |
| Explant | 0.9 |
| Death | 2.7 |
The EQ-5D is a standardized questionnaire that asks subjects to rate themselves (no problems, some problems, extreme problems) on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scale ranges from a minimum of 0 and a maximum of 100. A lower number indicates the participants experiences more problems and a higher number indicates the participants experiences fewer problems.
| units on a scale | Device - CEP Mitral Valve |
|---|---|
| Baseline | 63.1 ± 20.7 |
| 6 months | 75.4 ± 17.8 |
A linearized rate percentage is calculated by the following equation: \[(Total number of late adverse events in each category/total number of late patient years) x 100\]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact.
| Linearized rate percentage | Device - CEP Mitral Valve |
|---|---|
| Thromboembolism | 2.0 |
| Valve Thrombosis | 0.1 |
| All Bleeding Events | 5.8 |
| Major bleeding | 3.2 |
| Endocarditis | 0.3 |
| Hemolysis | 0.0 |
| Structural Valve Deterioration | 1.8 |
| Non-Structural Valve Dysfunction | 0.4 |
| Reoperation | 0.2 |
| Explant | 1.1 |
| Death | 5.3 |
Mean gradient is the average flow of blood through the mitral valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.
| mmHg | Device - CEP Mitral Valve |
|---|---|
| Baseline | 8.03 ± 5.42 |
| 8 years | 5.70 ± 2.85 |
Peak gradient is the maximum value measured of flow of blood through the mitral valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher valve is considered worse, and a lower value is considered better, but the value is dependent on the size and type of valve.
| mmHg | Device - CEP Mitral Valve |
|---|---|
| Baseline | 18.56 ± 9.63 |
| 8 years | 14.57 ± 6.62 |
Effective orifice area represents the cross-sectional area of the blood flow downstream of the mitral valve. Effective orifice area is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size and type of valve.
| cm^2 | Device - CEP Mitral Valve |
|---|---|
| Baseline | 1.39 ± 0.93 |
| 8 years | 1.90 ± 0.67 |
Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the mitral valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size of the patient and the size and type of valve.
| cm^2/m^2 | Device - CEP Mitral Valve |
|---|---|
| Baseline | 0.73 ± 0.48 |
| 8 years | 1.03 ± 0.38 |
Cardiac output is the amount of blood the heart pumps through the circulatory system in a minute. Cardiac output is evaluated by echocardiography over time. Normal cardiac output in healthy volunteers over 60 years of age was reported between 3.1 and 6.4 liters per minute. In general, a higher value is considered better, and a lower value is considered worse.
| L/min | Device - CEP Mitral Valve |
|---|---|
| Baseline | 4.70 ± 1.67 |
| 8 years | 6.02 ± 1.52 |
Cardiac index (CI) evaluated by echocardiography. Cardiac index is an assessment of the cardiac output value based on the patient's size. To obtain the cardiac index, divide the cardiac output by the person's body surface area (BSA). Cardiac Index is a useful marker of how well the heart is functioning as a pump by directly correlating the volume of blood pumped by the heart with an individual's body surface area. Normal cardiac output index in healthy volunteers over 60 years of age was reported between 1.1 and 3.2 L/min/m\^2. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size of the patient.
| L/min/m^2 | Device - CEP Mitral Valve |
|---|---|
| Baseline | 2.50 ± 0.86 |
| 8 years | 3.32 ± 0.91 |
Patients can experience an enlargement of the left ventricle (chamber) of their heart because it works harder with a defective heart valve. Left ventricular mass regression evaluates if the patient experiences a decrease in the size of the left ventricle (chamber) after the repair or replacement of their heart valve.
| grams | Device - CEP Mitral Valve |
|---|---|
| Baseline | 213.21 ± 90.50 |
| 8 years | 163.71 ± 54.50 |
The red blood cell (RBC) count is a test that measures the number of oxygen-carrying blood cells in your blood. The red blood cell count normal range for women is 4.2 to 5.4 10\^6 cells/microliters and for men is 4.7 to 6.1 10\^6 cells/microliters. A high red blood cell count may indicate that you have a condition that's preventing you from getting enough oxygen. A low RBC may be caused by an infection, or a medical condition related to anemia. In general, results either lower or higher than the normal range may indicate something is wrong.
| 10^6 cells/uL | Device - CEP Mitral Valve - 25mm | Device - CEP Mitral Valve - 27mm | Device - CEP Mitral Valve - 29mm | Device - CEP Mitral Valve - 31mm | Device - CEP Mitral Valve - 33mm |
|---|---|---|---|---|---|
| 6 months | 4.4 ± 0.6 | 4.4 ± 0.6 | 4.3 ± 0.6 | 4.3 ± 0.6 | 4.6 ± 0.5 |
| 1 year | 4.4 ± 0.5 | 4.3 ± 0.5 | 4.4 ± 0.5 | 4.2 ± 0.6 | 4.6 ± 0.4 |
| 2 years | 4.3 ± 0.5 | 4.4 ± 0.5 | 4.4 ± 0.6 | 4.3 ± 0.6 | 4.6 ± 0.3 |
| 3 years | 4.3 ± 0.5 | 4.4 ± 0.5 | 4.4 ± 0.7 | 4.3 ± 0.7 | 4.6 ± 0.3 |
| 4 years | 4.3 ± 0.5 | 4.4 ± 0.4 | 4.3 ± 0.5 | 4.4 ± 0.6 | 4.6 ± 0.3 |
| 5 years | 4.4 ± 0.5 | 4.4 ± 0.5 | 4.3 ± 0.6 | 4.2 ± 0.8 | 4.5 ± 0.4 |
| 6 years | 4.3 ± 0.6 | 4.4 ± 0.5 | 4.3 ± 0.6 | 4.3 ± 0.8 | 4.6 ± 0.4 |
| 7 years | 4.5 ± 0.5 | 4.3 ± 0.6 | 4.2 ± 0.7 | 4.1 ± 0.8 | 4.6 ± 0.3 |
| 8 years | 4.3 ± 0.6 | 4.4 ± 0.6 | 4.3 ± 0.6 | 4.1 ± 1.0 | 4.4 ± 0.4 |
Laboratory analysis of White Blood Cell (WBC) count on blood drawn from subject; WBC fight infection. The normal reference range for WBC count is 4.5 to 10.0 10\^3 cells/microliters. In general, results either lower or higher than the normal range can indicate something is wrong.
| 10^3 cells/uL | Device - CEP Mitral Valve - 25mm | Device - CEP Mitral Valve - 27mm | Device - CEP Mitral Valve - 29mm | Device - CEP Mitral Valve - 31mm | Device - CEP Mitral Valve - 33mm |
|---|---|---|---|---|---|
| 6 months | 6.9 ± 1.6 | 6.9 ± 1.7 | 7.2 ± 2.1 | 7.1 ± 2.2 | 6.7 ± 1.2 |
| 1 year | 7.1 ± 2.0 | 6.9 ± 2.0 | 7.1 ± 1.8 | 7.5 ± 2.0 | 7.2 ± 1.3 |
| 2 years | 6.9 ± 2.4 | 6.8 ± 1.9 | 7.2 ± 2.0 | 6.5 ± 1.8 | 5.8 ± 1.2 |
| 3 years | 6.5 ± 2.4 | 6.8 ± 1.8 | 7.0 ± 2.2 | 7.1 ± 2.2 | 6.1 ± 1.3 |
| 4 years | 6.9 ± 2.7 | 6.9 ± 1.9 | 7.6 ± 2.6 | 6.5 ± 1.6 | 6.0 ± 1.3 |
| 5 years | 6.2 ± 1.7 | 6.8 ± 1.7 | 7.3 ± 2.2 | 6.8 ± 1.7 | 6.9 ± 3.8 |
| 6 years | 6.4 ± 2.0 | 7.0 ± 1.6 | 6.9 ± 2.1 | 7.4 ± 1.8 | 5.9 ± 1.0 |
| 7 years | 6.8 ± 2.3 | 7.2 ± 2.2 | 7.0 ± 2.2 | 6.7 ± 2.1 | 6.1 ± 1.7 |
| 8 years | 6.0 ± 1.7 | 7.0 ± 2.1 | 7.9 ± 2.1 | 5.8 ± 1.5 | 6.6 ± 1.1 |
This is the laboratory analysis of Hemoglobin count on blood drawn from subjects. Hemoglobin is an oxygen-carrying protein in red blood cells. In males, a healthy hemoglobin level is between 13.2 and 16.6 g/dL. In females, a hemoglobin count of between 11.6 and 15 g/dL is considered normal and healthy. In general, results either lower or higher than the normal range can indicate something is wrong.
| g/dL | Device - CEP Mitral Valve - 25mm | Device - CEP Mitral Valve - 27mm | Device - CEP Mitral Valve - 29mm | Device - CEP Mitral Valve - 31mm | Device - CEP Mitral Valve - 33mm |
|---|---|---|---|---|---|
| 6 months | 12.4 ± 1.6 | 12.5 ± 1.5 | 12.8 ± 1.3 | 12.8 ± 1.6 | 13.7 ± 2.2 |
| 1 year | 12.9 ± 1.5 | 12.8 ± 1.7 | 13.3 ± 1.4 | 12.9 ± 1.7 | 13.9 ± 1.4 |
| 2 years | 12.5 ± 2.3 | 13.2 ± 1.4 | 13.3 ± 1.7 | 13.2 ± 1.9 | 14.0 ± 1.1 |
| 3 years | 12.9 ± 1.5 | 13.0 ± 1.5 | 13.1 ± 1.4 | 13.1 ± 2.0 | 14.0 ± 1.8 |
| 4 years | 12.6 ± 1.5 | 13.0 ± 1.5 | 12.9 ± 1.6 | 13.6 ± 1.7 | 14.2 ± 0.7 |
| 5 years | 13.1 ± 1.4 | 13.0 ± 1.7 | 13.0 ± 1.6 | 13.0 ± 2.3 | 13.8 ± 1.4 |
| 6 years | 12.5 ± 1.7 | 12.7 ± 1.7 | 12.7 ± 1.3 | 13.4 ± 2.0 | 14.4 ± 1.1 |
| 7 years | 12.8 ± 1.6 | 12.7 ± 1.7 | 12.3 ± 1.8 | 12.7 ± 2.3 | 14.0 ± 1.5 |
| 8 years | 12.5 ± 1.7 | 12.8 ± 2.0 | 13.1 ± 1.4 | 12.8 ± 2.7 | 13.6 ± 1.8 |
This is laboratory analysis of Hematocrit percentage on blood drawn from subjects. A hematocrit test measures the proportion of red blood cells in your blood. Red blood cells carry oxygen throughout your body. Having too few or too many red blood cells can be a sign of certain diseases. Normal hematocrit ranges for adult females are 36% to 44% and for adult males are 41% to 50%. In general, results either lower or higher than the normal range can indicate something is wrong.
| Percentage of red blood cells | Device - CEP Mitral Valve - 25mm | Device - CEP Mitral Valve - 27mm | Device - CEP Mitral Valve - 29mm | Device - CEP Mitral Valve - 31mm | Device - CEP Mitral Valve - 33mm |
|---|---|---|---|---|---|
| 6 months | 38.0 ± 4.3 | 37.9 ± 4.3 | 38.7 ± 3.8 | 38.6 ± 4.8 | 40.7 ± 5.9 |
| 1 year | 39.4 ± 4.0 | 38.6 ± 4.3 | 39.7 ± 4.1 | 38.6 ± 4.8 | 41.6 ± 3.6 |
| 2 years | 39.0 ± 4.5 | 39.6 ± 3.7 | 40.0 ± 4.7 | 39.9 ± 5.1 | 41.6 ± 3.1 |
| 3 years | 39.4 ± 4.4 | 39.1 ± 4.3 | 39.5 ± 3.8 | 39.4 ± 5.2 | 41.7 ± 5.0 |
| 4 years | 39.0 ± 4.7 | 39.4 ± 3.9 | 39.2 ± 4.3 | 40.9 ± 4.3 | 42.4 ± 1.2 |
| 5 years | 40.0 ± 4.5 | 39.7 ± 4.6 | 39.8 ± 4.7 | 39.4 ± 6.5 | 41.0 ± 3.7 |
| 6 years | 38.7 ± 4.8 | 39.3 ± 4.6 | 38.8 ± 4.0 | 40.3 ± 5.9 | 42.3 ± 3.1 |
| 7 years | 39.8 ± 4.8 | 37.3 ± 8.2 | 38.1 ± 5.1 | 38.1 ± 6.1 | 42.4 ± 4.4 |
| 8 years | 38.6 ± 5.5 | 39.6 ± 5.1 | 39.8 ± 4.2 | 38.5 ± 7.4 | 40.9 ± 5.3 |
Laboratory Analysis of reticulocytes on blood drawn from subjects. Reticulocytes are newly produced immature red blood cells; a reticulocyte blood test measures the amount of these cells in the blood. The reference range for reticulocytes is 0.5 - 2.6 % of red blood cells. In general, results either lower or higher than the normal range can indicate something is wrong.
| Percentage of reticulocytes | Device - CEP Mitral Valve - 25mm | Device - CEP Mitral Valve - 27mm | Device - CEP Mitral Valve - 29mm | Device - CEP Mitral Valve - 31mm | Device - CEP Mitral Valve - 33mm |
|---|---|---|---|---|---|
| 6 months | 1.2 ± 0.6 | 1.4 ± 0.7 | 1.4 ± 0.6 | 1.2 ± 0.6 | 1.1 ± 0.4 |
| 1 year | 1.4 ± 0.6 | 1.4 ± 0.6 | 1.3 ± 0.5 | 1.3 ± 0.5 | 1.2 ± 0.6 |
| 2 years | 1.5 ± 0.6 | 1.4 ± 0.5 | 1.4 ± 0.6 | 1.2 ± 0.4 | 2.9 ± 4.9 |
| 3 years | 1.5 ± 0.5 | 1.5 ± 0.7 | 1.4 ± 0.5 | 1.3 ± 0.5 | 1.2 ± 0.6 |
| 4 years | 1.4 ± 0.5 | 2.8 ± 10.3 | 1.6 ± 0.5 | 1.2 ± 0.4 | 1.1 ± 0.4 |
| 5 years | 1.4 ± 0.5 | 2.6 ± 6.6 | 1.5 ± 0.6 | 1.4 ± 0.4 | 1.3 ± 0.5 |
| 6 years | 1.5 ± 0.5 | 1.5 ± 0.6 | 1.4 ± 0.6 | 1.4 ± 0.4 | 1.1 ± 0.3 |
| 7 years | 1.6 ± 0.4 | 2.0 ± 2.8 | 1.7 ± 1.0 | 1.3 ± 0.5 | 1.2 ± 0.2 |
| 8 years | 1.6 ± 0.5 | 1.5 ± 0.6 | 2.2 ± 2.8 | 1.6 ± 0.8 | 1.5 ± 0.3 |
This is laboratory analysis of Platelet count on blood drawn from subjects. The purpose of platelets is to create hemostasis, which is the prevention of hemorrhaging (bleeding) and the process of keeping blood inside the vessel walls. A normal platelet range is 150 to 450 10\^3 cells/microliter. In general, results either lower or higher than the normal range can indicate something is wrong.
| 10^3 cells/microliter | Device - CEP Mitral Valve - 25mm | Device - CEP Mitral Valve - 27mm | Device - CEP Mitral Valve - 29mm | Device - CEP Mitral Valve - 31mm | Device - CEP Mitral Valve - 33mm |
|---|---|---|---|---|---|
| 6 months | 242.2 ± 85.7 | 218.5 ± 83.7 | 211.6 ± 68.9 | 202.0 ± 49.2 | 202.0 ± 58.4 |
| 1 year | 224.3 ± 64.9 | 214.7 ± 76.9 | 201.6 ± 69.1 | 196.0 ± 42.1 | 201.5 ± 54.2 |
| 2 years | 217.1 ± 66.8 | 208.9 ± 70.2 | 208.4 ± 80.5 | 190.6 ± 35.9 | 175.9 ± 31.0 |
| 3 years | 208.0 ± 87.2 | 210.8 ± 80.2 | 200.3 ± 86.6 | 197.4 ± 45.8 | 191.0 ± 48.9 |
| 4 years | 207.2 ± 79.7 | 212.0 ± 78.6 | 213.8 ± 108.2 | 188.1 ± 45.6 | 190.9 ± 40.3 |
| 5 years | 203.5 ± 64.5 | 208.1 ± 74.6 | 207.4 ± 123.8 | 177.7 ± 37.6 | 212.2 ± 65.7 |
| 6 years | 197.0 ± 61.3 | 214.3 ± 90.9 | 224.0 ± 197.2 | 190.4 ± 35.0 | 185.3 ± 27.3 |
| 7 years | 203.4 ± 60.2 | 219.6 ± 77.3 | 237.2 ± 197.9 | 202.4 ± 46.7 | 181.5 ± 37.1 |
| 8 years | 175.1 ± 48.4 | 225.1 ± 92.3 | 198.8 ± 53.6 | 189.3 ± 40.5 | 177.8 ± 27.9 |
The serum lactate dehydrogenase (LDH) test looks for signs of damage to the body's tissues. Normal levels of LDH in the blood can vary depending on the lab but usually range between 140 units per liter (U/L) to 280 U/L for adults and tend to be higher for children and teens. In general, results either lower or higher than the normal range can indicate something is wrong.
| U/L | Device - CEP Mitral Valve - 25mm | Device - CEP Mitral Valve - 27mm | Device - CEP Mitral Valve - 29mm | Device - CEP Mitral Valve - 31mm | Device - CEP Mitral Valve - 33mm |
|---|---|---|---|---|---|
| 6 months | 241.4 ± 48.4 | 247.3 ± 100.1 | 322.5 ± 189.8 | 274.2 ± 141.0 | 300.5 ± 182.0 |
| 1 year | 232.7 ± 44.0 | 250.2 ± 100.4 | 294.5 ± 145.0 | 229.5 ± 103.1 | 472.3 ± 223.8 |
| 2 years | 228.7 ± 54.0 | 231.9 ± 82.0 | 263.8 ± 103.1 | 209.1 ± 51.6 | 405.3 ± 219.8 |
| 3 years | 243.1 ± 41.4 | 227.0 ± 66.0 | 274.7 ± 102.0 | 240.2 ± 56.4 | 332.5 ± 149.2 |
| 4 years | 243.0 ± 53.1 | 220.1 ± 45.0 | 247.8 ± 33.7 | 251.0 ± 43.7 | 286.0 ± 127.3 |
| 5 years | 227.3 ± 23.7 | 227.3 ± 42.5 | 221.4 ± 31.3 | 238.5 ± 19.1 | 287.0 ± 118.8 |
| 6 years | 256.7 ± 71.3 | 248.5 ± 94.4 | 245.3 ± 33.8 | 269.3 ± 43.0 | 393 |
| 7 years | — | 202.5 ± 109.7 | 255.8 ± 24.2 | 254.0 ± 22.0 | 200.0 |
| 8 years | 253.0 | 254.5 ± 56.1 | 257.4 ± 28.4 | 369.7 ± 189.7 | 423.0 |
Laboratory analysis of Plasma Free Hemoglobin (Pf Hgb) of blood drawn from subject. This blood test measures the level of free hemoglobin in the plasma (liquid portion of the blood). The reference range for plasma free hemoglobin is 0.0 to 15.2 mg/dL. In general, values higher than this can indicate something is wrong.
| mg/dL | Device - CEP Mitral Valve - 25mm | Device - CEP Mitral Valve - 27mm | Device - CEP Mitral Valve - 29mm | Device - CEP Mitral Valve - 31mm | Device - CEP Mitral Valve - 33mm |
|---|---|---|---|---|---|
| 6 months | 10.7 ± 8.6 | 8.3 ± 7.2 | 14.4 ± 23.4 | 17.8 ± 35.3 | 20.1 ± 19.0 |
| 1 year | 16.3 ± 17.5 | 11.7 ± 11.6 | 11.5 ± 13.5 | 18.3 ± 25.7 | 12.6 ± 8.0 |
| 2 years | 15.2 ± 19.3 | 14.0 ± 18.4 | 7.9 ± 6.5 | 17.0 ± 14.0 | 12.3 ± 7.6 |
| 3 years | 15.8 ± 20.1 | 11.6 ± 14.2 | 9.0 ± 8.7 | 7.4 ± 5.3 | 15.4 ± 8.9 |
| 4 years | 26.3 ± 35.2 | 8.4 ± 7.5 | 13.6 ± 29.9 | 16.2 ± 21.8 | 10.0 ± 3.2 |
| 5 years | 13.8 ± 17.6 | 7.5 ± 5.8 | 9.7 ± 9.5 | 9.6 ± 10.9 | 17.0 ± 7.8 |
| 6 years | 14.0 ± 15.0 | 6.6 ± 4.1 | 12.2 ± 13.7 | 12.1 ± 11.9 | 29.8 ± 40.2 |
| 7 years | 20.6 ± 32.1 | 12.3 ± 24.5 | 20.7 ± 31.5 | 8.5 ± 5.6 | 9.0 ± 4.8 |
| 8 years | 14.2 ± 12.2 | 11.5 ± 9.7 | 12.5 ± 11.2 | 13.7 ± 11.8 | 8.0 ± 2.9 |
Haptoglobin is a protein produced by your liver. It binds with hemoglobin, which is a protein found in red blood cells. When red blood cells are destroyed, they release hemoglobin. The released hemoglobin is called "free hemoglobin." Haptoglobin attaches to the free hemoglobin to create a haptoglobin-hemoglobin complex. This complex travels to the liver, where it's removed from the body. A normal haptoglobin level falls between 45 and 200 milligrams of haptoglobin per deciliter of blood. In general, results either lower or higher than the normal range can indicate something is wrong.
| mg/dL | Device - CEP Mitral Valve - 25mm | Device - CEP Mitral Valve - 27mm | Device - CEP Mitral Valve - 29mm | Device - CEP Mitral Valve - 31mm | Device - CEP Mitral Valve - 33mm |
|---|---|---|---|---|---|
| 6 months | 118.7 ± 59.0 | 143.9 ± 90.8 | 118.0 ± 63.6 | 119.2 ± 65.5 | 70.9 ± 68.4 |
| 1 year | 110.0 ± 52.0 | 120.8 ± 68.9 | 107.9 ± 67.0 | 128.3 ± 60.5 | 123.7 ± 62.1 |
| 2 years | 110.1 ± 38.9 | 127.1 ± 76.2 | 124.2 ± 57.6 | 101.8 ± 48.3 | 109.8 ± 89.4 |
| 3 years | 103.6 ± 46.6 | 139.2 ± 80.3 | 96.2 ± 52.5 | 117.0 ± 36.1 | 109.0 ± 19.8 |
| 4 years | 111.4 ± 54.9 | 139.9 ± 77.9 | 97.6 ± 49.6 | 96.9 ± 53.5 | 81.1 ± 113.0 |
| 5 years | 79.0 ± 49.1 | 152.4 ± 81.5 | 111.6 ± 56.3 | 80.2 ± 91.6 | 120.1 ± 168.1 |
| 6 years | 118.7 ± 95.5 | 109.8 ± 71.4 | 103.6 ± 58.6 | 126.8 ± 37.9 | 151.0 ± 70.7 |
| 7 years | — | 85.2 ± 78.0 | 107.2 ± 72.6 | 51.7 ± 40.2 | 239.0 |
| 8 years | 115.0 | 129.0 ± 23.3 | 106.4 ± 40.0 | 96.0 ± 22.6 | 117.0 |
Collected over Events occurring from baseline through eight years of follow-up post implant.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Device - CEP Mitral Valve | 88/329 (26.7%) | 281/329 (85.4%) | 206/329 (62.6%) |
| Event | Device - CEP Mitral Valve |
|---|---|
| ARRHYTHMIACardiac disorders | 99/329 |
| RESPIRATORY COMPLICATIONRespiratory, thoracic and mediastinal disorders | 86/329 |
| OTHERGeneral disorders | 79/329 |
| CARDIAC FAILURECardiac disorders | 73/329 |
| BLEEDING - MAJORBlood and lymphatic system disorders | 60/329 |
| INFECTION / INFLAMMATIONInfections and infestations | 59/329 |
| GASTRO-INTESTINAL COMPLICATIONGastrointestinal disorders | 53/329 |
| CARDIAC CONDUCTION DISTURBANCECardiac disorders | 52/329 |
| PLEURAL EFFUSIONCardiac disorders | 49/329 |
| RENAL COMPLICATIONRenal and urinary disorders | 36/329 |
| Event | Device - CEP Mitral Valve |
|---|---|
| OTHERGeneral disorders | 78/329 |
| ARRHYTHMIACardiac disorders | 70/329 |
| RESPIRATORY COMPLICATIONRespiratory, thoracic and mediastinal disorders | 62/329 |
| PLEURAL EFFUSIONCardiac disorders | 44/329 |
| ANEMIABlood and lymphatic system disorders | 36/329 |
| INFECTION / INFLAMMATIONInfections and infestations | 35/329 |
| CARDIAC CONDUCTION DISTURBANCECardiac disorders | 34/329 |
| RENAL COMPLICATIONRenal and urinary disorders | 31/329 |
| URINARY TRACT INFECTIONRenal and urinary disorders | 30/329 |
| HEMATOLOGICAL DISORDERBlood and lymphatic system disorders | 27/329 |
Subjects implanted with a Carpentier-Edwards PERIMOUNT Magna Mitral heart valve.
| Age, Continuous(Years) | Device - CEP Mitral Valve |
|---|---|
| Mean | 69.7 ± 10.7 |
| Sex: Female, Male(Participants) | Device - CEP Mitral Valve |
|---|---|
| Female | 201 |
| Male | 128 |
| Race and Ethnicity Not Collected(Participants) | Device - CEP Mitral Valve |
|---|
| Region of Enrollment(participants) | Device - CEP Mitral Valve |
|---|---|
| Canada | 55 |
| Europe | 105 |
| United States | 169 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No — Individual participant data will not be available to other researchers.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Edwards Lifesciences